Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas

European Journal of Nuclear Medicine

Volumn 25, Issue 7, 1998, Pages 729-735

  Nuutinen, Joanne ^a   Leskinen, Sirkku ^a   Lindholm, Paula ^a   Söderström, Karl Ove ^a   Någren, Kjell ^a   Huhtala, Sakke ^b   Minn, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Carbon 11 methionine; Lymphoma; Malignancy grade; Positron emission tomography; Survival

Indexed keywords

METHIONINE C 11;

ADULT; AGED; ARTICLE; BODY SURFACE; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEAN BODY WEIGHT; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; CARBON RADIOISOTOPES; FEMALE; FLOW CYTOMETRY; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; METHIONINE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0031867733     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050276     Document Type: Article

References (37)

1. De Wolf-Peeters C, Caillou B, Diebold J, et al. Reproducibility and prognostic value of different non-Hodgkin's lymphoma classifications: study based on the clinicopathologic relations found in the EORTC trial (20751). Eur J Cancer 1985; 21: 579-584.
2. Joensuu H, Ristamäki R, Söderström K-O, Jalkanen S. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma. J Clin Oncol 1994; 10: 2167-2175.
3. Harris NL, Jaffe ES, Stein H, et al. Revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
4. Lapela M, Leskinen S, Minn H, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
5. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
6. 18F)fluorodeoxyglucose in brain tumours. A powerful diagnostic and prognostic tool. Invest Radiol 1987; 22: 360-371.
7. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumours using PET. J Nucl Med 1991; 32: 1508-1512.
8. Miyazawa H, Arai T, Iio M, Ito M, Hara T. PET in imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993; 34: 1886-1891.
9. 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991; 64: 1121-1124.
10. 11C]L-methionine uptake in gliomas. Neurosurgery 1989; 25: 720-729.
11. Fujiwara T, Matsuzawa T, Kubota K, et al. Relationship between histologic type of primary lung cancer and carbon-11-L-methionine uptake with positron emission tomography. J Nucl Med 1989; 30: 33-37.
12. Lapela M, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med 1994; 35: 1618-1623.
13. Leskinen-Kallio S, Ruotsalainen U, Någren K, Teräs M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32: 1211-1218.
14. Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
15. Hoffman RM. Alterated methionine metabolism, DNA methylation and oncogenic expression in carcinogenesis. Biochem Biophys Acta 1984; 738: 49-87.
16. Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumour cell lines. J Cell Physiol 1984; 119: 29-34.
17. Wheatley DN. On the problem of linear in corporation of amino acids into cell proteins. Experientia 1982; 38: 818-829.
18. Stern PH, Hoffman RM. Elevated overall rates of transmethylation in cell lines from diverse human tumours. In vitro 1984; 20: 663-670.
19. Olefsky JM. Obesity. In: Wilson JD, Barunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK, eds. Harrison's principles of internal medicine, vol 1. New York: McGraw-Hill; 1991: 411.
20. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860.
21. Shipp MA, Harrington DP, Anderson JR, et al. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
22. 11C]methionine. J Nucl Med 1987; 28: 1037-1040.
23. 11C]raclopride. J Labelled Compounds Radiopharm 1995; 37: 103-105.
24. 11C]methionine.In: Mazoyer M, Heiss WD, Comar D, eds. PET studies on amino acid metabolism and protein synthesis. Dordrecht: Kluwer Academic; 1993: 81-87.
25. Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanners. IEEE Trans Nucl Sci 1988; 35: 721-725.
26. Minn H, Lapela M, Klemi P, et al. Prediction of survival with fluorine-18 fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907-1911.
27. Woodard HW, Bigler RB, Freed B, Russ G. Expression of tissue isotope distribution. J Nucl Med 1975; 16: 958.
28. Zasadny K, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.
29. 11C]Methionine quantitation in cancer PET studies. J Comput Assist Tomogr 1992; 16:468-474.
30. Patlak CS, Balsberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584.
31. The non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of Working Formulation for clinical usage. Cancer 1982; 49: 2112.
32. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphomas. Lancet 1988; 1: 292.
33. Joensuu H, Klemi PJ, Söderström K-O, Jalkanen S. Comparison of S-phase fraction, Working Formulation, and Kiel classification in non-Hodgkin's lymphoma. Cancer 1991; 68: 1564.
34. SAS/STAT Software: Changes and enhancements through release 6.11. Cary, NC: SAS Institute Inc., 1996.
35. 11C]methionine quantitation in cancer PET studies. J Comput Assist Tomogr 1992; 16: 468-474.
36. Lindholm P, Leskinen S, Lapela M, et al. 11-C-methionine uptake in squamous cell head and neck cancer. J Nucl Med 1998.
37. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, Arimizu N. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 3: 187-191.